Search
Alclofenac
go.drugbank.com/drugs/DB13167ApprovedWithdrawnAlclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.
Parsaclisib
go.drugbank.com/drugs/DB14867InvestigationalParsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).
Tofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalTofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. … It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.
Perampanel
go.drugbank.com/drugs/DB08883ApprovedInvestigationalPerampanel is a noncompetitive AMPA glutamate receptor antagonist. … It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.
Categories: AMPA Receptor Antagonists, Noncompetitive AMPA Glutamate Receptor AntagonistTislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1).
Categories: Programmed Death Receptor-1 Blocking AntibodyBromfenac
go.drugbank.com/drugs/DB00963ApprovedWithdrawnNon-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] … Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes.
Regadenoson
go.drugbank.com/drugs/DB06213ApprovedInvestigationalRegadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
Categories: Adenosine A receptor agonists, Adenosine A2 Receptor AgonistsQuinacrine
go.drugbank.com/drugs/DB01103InvestigationalAn acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. … It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
Anthoxanthum odoratum
go.drugbank.com/drugs/DB14163ApprovedAnthoxanthum odoratum allergenic extract is used in allergenic testing.
Mixtures: ORALAIR 100 IR + 300 IR Sublingualtabletten, ORALAIR 100 IR + 300 IR Sublingualtabletten